OrganiGram Holdings (OGI) Stock

Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco. Analysts expect revenue and adjusted EBITDA to grow significantly in FY25 and FY26, making the stock a compelling buy.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market innovation. FAST™ products deliver up to ~50% faster onset and improved bioavailability delivering nearly double the cannabinoids at peak effect compared to traditional ed.

Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tra.

Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued.

Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - AGP Pablo Zuanic - Zuanic & Associates Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Keyla, and I'll be your conference operator today.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business. Subject to the terms of the Agreement, the Company expects to supply 1,700 kilograms of high-quality, indoor-grown dried cannabis flower to Avida Medical in the UK over.

This week, investors in marijuana stocks are remaining optimistic about the sector. The cannabis industry is constantly evolving, making it important to adapt to market changes. The volatile nature of trading in marijuana stocks can make it difficult to predict patterns, so staying informed about news and events is essential.

Here is a comparison of the performance of OrganiGram (OGI) and ResMed (RMD) with their sector so far this year.